Showing results (221-230 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 8, 2006
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanomaMichael G Smylie, Ralph Wong, Catalin Mihalcioiu, et al.
Investigational New Drugs|March 16, 2006
Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injectionG W Boswell, D R Miles, P A Thiemann, et al.
Investigational New Drugs|October 6, 2006
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaRichard Kefford, Jane McNeil Beith, Guy Arthur Van Hazel, et al.
Investigational New Drugs|July 14, 2005
Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDPBeata Kosmider, Izabela Wojcik, Regina Osiecka, et al.
Investigational New Drugs|April 1, 1992
Activity of a recombinant transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming unitsD D Von Hoff, M H Marshall, D C Heimbrook, et al.
Investigational New Drugs|May 8, 2007
A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistanceGene L Bidwell, Aisha N Davis, Izabela Fokt, et al.
Investigational New Drugs|December 5, 2022
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trialsShigemasa Takamizawa, Yuki Katsuya, Yi-Ning Chen, et al.
Investigational New Drugs|January 1, 1987
Inactivation of human cells cultivated in vitro by the new mitotic inhibitors NY 4137 and NY 4138M E Nygaard, E O Pettersen, J M Dornish, et al.
Investigational New Drugs|January 1, 1987
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanomaD A Amato, H Bruckner, D Guerry, et al.
Investigational New Drugs|January 8, 2021
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trialJeffrey A How, Amir Jazaeri, Shannon N Westin, et al.
Pageof 372